Tumor markers of pancreatic cancer cells secreted mainly refers to the body fluids or tissues, or loss of material, or the host of new biological reaction in vivo and into the body fluids or tissue material. These substances, some do not exist in the normal human body and only found in embryos, and some body content in cancer patients than normal body content. By determining the existence or content of the tumor can be aided diagnosis, of course, guiding treatment, monitoring and prediction of recurrence or metastasis. Clinical application of tumor markers for more than 100 kinds of laboratory tests from the perspective of tumor markers can be divided into two serum tumor markers and tissue tumor markers.
Pancreatic cancer tumor markers in cancer diagnosis and monitoring of film, there are a large number of serum tumor markers are applied, which are commonly used in clinical carbohydrate antigen CA19-9, CA50, CA242, carcinoembryonic antigen CEA, pancreas-specific antigens.
(1) CA19-9: is the expression of high molecular weight mucin carbohydrate sites, it is not organ specific, can be elevated in a variety of adenocarcinomas, but in the film adenocarcinoma inspection with high sensitivity, The positive rate of 85% or more, is the film a more reliable marker for adenocarcinoma. Can be used to determine the prognosis, such as preoperative CA19-9 values increased to normal range after surgery, the prognosis is good.
(2) CA242: the employing mice immunized with colon cancer cells by a monoclonal antibody. In normal pancreas, colon exists, but the expression is low, increased in the membrane adenocarcinoma. Positive diagnosis rate of 70% _80
(3) CA50: is employing mice immunized with colon cancer cells by a monoclonal antibody. Its sensitivity and CA19-9 is similar to slightly lower specificity.
(4) CEA: it exists in the embryo with a number of gastrointestinal epithelial cell surface of malignant tissue, is a glycoprotein. In the colon, membrane adenocarcinoma, breast cancer, lung cancer can be increased. Because specificity is not high, but the level and tumor size, recurrence, and lower positive rate of early film adenocarcinoma (30%), the CEA as a diagnostic of little significance to determine the clinical effect of surgery and estimated only for patients prognosis significance.
(5) pancreatic tumor marker, pancreas-specific antigen (pancreatic specific antigen, PSA): PSA is synthesized in pancreatic acinar an acidic glycoprotein. Secreted into the pancreas, may be the ideal diagnostic film adenocarcinoma, a tumor marker. Elevated serum PSA in patients with pancreatic cancer, the positive rate of 70% and a specificity of 95%. If the combined detection of both membrane carcinoma-associated antigen (PACC) to the positive rate to 95%. However, PSA in benign pancreatic diseases is also increasing, the positive rate reached 29%, in non-pancreatic tumors positive rate of 5.7%.
The study showed that the combination of the above, such as tumor markers, cancer diagnosis in the membrane sensitivity and specificity on both will be increased.